Objectives

• Expanded indications of liver transplantation for HCC
• Updated outcomes of liver transplantation for unresectable CRLM
• Critical role of combining non-transplant modalities with liver transplantation

Agenda

• Introduction
• How to select patients beyond size and number (Anjana Pillai)
• Downstaging and bridging therapies (Sherrie Bhoori)
• Q&A moderated by Taizo Hibi and Gonzalo Sapisochin

Speakers

Anjana Pillai, MD, is a board-certified gastroenterologist and transplant hepatologist who specializes in the management of chronic liver diseases. Dr Pillai is the medical director of the multidisciplinary liver tumor program, which encompasses multiple specialists with expertise in benign and malignant tumors of the liver. As part of the University of Chicago Medicine Comprehensive Cancer Center, she provides individualized treatment options to her patients. Dr Pillai is an active researcher with a focus on hepatocellular carcinoma and cholangiocarcinoma. Additionally, she works with colleagues from the liver tumor program to deliver a robust research infrastructure that offers multiple phase II and III trials for individualized treatment plans for each patient.

Sherrie Bhoori, MD, born a Parsee Zoroastrian in India in 1973, Italy adopted Sherrie Bhoori and her family. She trained in Milan, earning her medical degree in 1996 with a speciality in Gastroenterology and Hepatology in 2004. After winning several scholarships funded by the Italian Association against Cancer (AIRC) and focussing on Artificial Nutrition in the cancer setting, Dr Bhoori became an active member of Professor Vincenzo Mazzaferro’s staff. There she trained and specialized in post-liver transplantation management, organ allocation and management of hepatocellular carcinoma. Dr Bhoori is co-investigator of several trials focusing on primary liver cancer and enjoys educational activity at all levels.

Moderators

Taizo Hibi is the Professor and Chairman of the Department of Transplantation and Pediatric Surgery, Kumamoto University (Kumamoto, Japan). He graduated from Keio University (Tokyo) and completed his surgical residency and fellowships at National Cancer Center Hospital (Tokyo) and Keio University, and University of Miami (Florida, U.S.) Dr. Hibi has extensive experience both in abdominal organ transplant surgery and surgical oncology, particularly in the hepatobiliary and pancreatic field. He and his international colleagues have established the concept of “Transplant Oncology,” a fusion of transplantation medicine and oncology, for eradication of cancer. Dr. Hibi has published over 150 peer-reviewed articles. He serves as an editorial board member of internationally recognized surgical journals and as a councilor of multiple national/international academic associations and societies.

Gonzalo Sapisochin, MD, PhD, MSc, is an Associate Professor in the Division of General Surgery at UHN in the Department of Surgery. He graduated with his Medical Degree from the University Compluense of Madrid, Spain and then did his residency at the Vall d’Hebron Hospital in Barcelona, Spain. His Fellowship in Abdominal Transplant and HPB Surgical Oncology was done at U of T, Toronto General Hospital. Gonzalo has many publications and grants; has won several awards; and has presented at international meetings.

This Webinar is Supported by Bridge to Life

ILTS would like to thank Bridge to Life for their generous support for the production of this webinar. Bridge to Life has had no influence on the content, and full editorial control remains the sole responsibility of ILTS.

Bridge to Life is a leading supplier of preservation solutions globally with a focus on innovation in organ preservation and machine perfusion. Through a strong focus on collaboration with surgeons and transplant professionals, Bridge to Life continues to explore emerging science and preservation technologies. https://bridgetolife.eu